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Abstract 
Elevated serum uric acid (SUA) level is known to be a prognostic factor in patients with acute 
coronary syndrome (ACS). However, the pathogenesis of the relation between SUA level and 
coronary plaque characteristics has not been fully evaluated. The aim of this study was to 
investigate the relation between SUA level and plaque composition of non-culprit lesions in ACS 
patients. A total of 81 ACS patients who underwent intravascular ultrasound (IVUS)-guided 
percutaneous coronary intervention were included. They were classified into 3 groups according 
to tertiles of SUA level. Utilizing integrated backscatter (IB)-IVUS system, tissue components 
were classified into 4 categories: calcium deposits, dense fibrosis, fibrosis, and lipid. Tertiles of 
SUA level were as follows: low tertile, <5.0 mg/dl; intermediate tertile, 5.0 to 6.4 mg/dl; and high 
tertile, >6.4 mg/dl. There was a trend toward greater vessel volume in the high tertile group than 
in the low and intermediate tertile groups (19.4 ± 3.7 vs. 17.4 ± 4.4 vs. 16.7 ± 4.1 mm
3
/mm, p = 
0.05). There was no significant difference in lumen volume between the 3 groups. Plaque volume 
was significantly greater in the high tertile group than in the low tertile group (8.6 ± 2.4 vs. 6.7 ± 
2.2 mm
3
/mm, p = 0.01). IB-IVUS analysis demonstrated greater lipid (59.1 ± 9.1% vs. 49.7 ± 
10.9% vs. 51.1 ± 9.3%, p = 0.001) and less fibrous components (36.8 ± 7.8% vs. 44.3 ± 7.8% vs. 
43.2 ± 6.7%, p <0.001) in the high tertile group than in the low and intermediate tertile groups. 
Multivariate analysis showed high SUA as an independent predictor of increasing lipid volume. 
In conclusion, elevated SUA level is associated with greater lipid content of coronary plaque in 
patients with ACS than in patients with normal levels. 
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Elevated serum uric acid (SUA) level is associated with cardiovascular events in patients with 
coronary risk factors such as hypertension or diabetes.
1,2
 It is also a prognostic factor in patients 
with acute coronary syndrome (ACS), especially ST-segment elevation myocardial infarction 
(STEMI).
3-5
 However, the pathogenesis of the relation between SUA level and coronary plaque 
characteristics has not been fully evaluated. Integrated backscatter-intravascular ultrasound 
(IB-IVUS) allows quantitative detection of coronary plaque components in vivo.
6-8
 Increased 
lipid-rich plaque is an independent predictor of cardiovascular events after percutaneous coronary 
intervention (PCI).
9 
It is also associated with no-reflow and slow flow phenomenon during 
PCI.
10,11
 The aim of this study was to investigate the relation between SUA level and plaque 
composition of non-culprit lesions in ACS patients. 
 
Methods 
From April 2012 to December 2014, a total of 313 ACS patients underwent PCI at Chiba 
University Hospital. Patients were considered eligible for this study when SUA measurement on 
admission was available and IVUS-guided PCI was performed. The major criteria for exclusion 
were patients receiving antihyperuricemic agents before admission, hemodialysis, no stent 
implantation, emergent surgery or mechanical support (e.g., extracorporeal membrane 
oxygenation), cardiopulmonary arrest, in-hospital adverse events, and a target lesion in stented 
segment. Patients who had no analyzable non-culprit plaque (plaque burden >20% and at least 5 
mm length) were also excluded. Thus 81 patients were included in the study (Figure 1). They 
were classified into 3 groups according to tertiles of SUA level. 
ACS was defined as unstable angina or acute myocardial infarction (MI) <48 hours from 
the onset. The diagnosis of acute MI was based on the third universal definition of myocardial 
infarction.
12
 Unstable angina was diagnosed using Braunwald’s criteria plus documentation of 
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significant coronary artery disease on coronary angiography.
13
 The ethics committee of Chiba 
University approved the study. 
All gray-scale IVUS and IB-IVUS were performed after intracoronary administration of 
isosorbide dinitrate 1–2 mg. They were acquired with a commercially available IVUS imaging 
system (VISIWAVE, Terumo, Tokyo, Japan) using a 43-MHz mechanically rotating IVUS 
catheter (View IT, Terumo) with a motorized transducer pullback speed of 0.5 mm/s. All IVUS 
measurements were performed by an experienced investigator, who was unaware of the patients’ 
clinical characteristics, according to the American College of Cardiology Clinical Expert 
Consensus Document on Standards for Acquisition, Measurement, and Reporting of Intravascular 
Ultrasound Studies.
14
 Offline analysis including IB-IVUS analysis was performed using a 
computerized system (VISIATLAS, Terumo). IVUS measurement was performed from the 
ostium of the culprit artery to the site 5-mm proximal to the proximal edge of the stent. For each 
0.5 mm of axial length, lumen and external elastic membrane cross-sectional areas were manually 
measured. Volumetric IVUS data was presented as total volume per lesion length (mm
3
/mm) for 
correcting the differences of lesion length.
8, 15
 Tissue components were classified into 4 
categories: calcium deposits (red), dense fibrosis (yellow), fibrosis (green), and lipid (blue) 
according to signal level.
16
 The percentage of lipid, fibrosis, dense fibrosis, and calcium deposits 
plaque volume (each component volume/plaque volume  100) were calculated. 
Statistical analysis was performed with SAS statistical software package version 9.4 
(SAS Institute, Cary, NC). Data are expressed as the mean ± SD or frequency (%). Continuous 
variables were compared using analysis of variance (ANOVA). Categorical variables were 
compared with chi-square statistics or Fisher’s exact test. A value of p <0.05 was considered 
significant. Univariate analysis for variables in Table 1 was performed using linear regression 
analysis of rank-transformed outcomes. Including only variables with a p value of <0.2 on 
5 
 
univariate analysis, multivariate analysis was performed using multiple linear regression analysis 
of rank-transformed outcomes. 
 
Results 
Tertiles of SUA level were as follows: low tertile, <5.0 mg/dl; intermediate tertile, 5.0 to 
6.4 mg/dl; and high tertile, >6.4 mg/dl. Table 1 lists baseline characteristics. Table 2 shows IVUS 
measurements. IB-IVUS analysis demonstrated greater lipid and less fibrous components in the 
high tertile group than in the low and intermediate tertile groups (Figure 2). Figure 3 shows the 
representative IVUS images in patients with low and high SUA levels. Multivariate analysis 
showed high SUA level as an independent predictor of greater lipid plaque volume (Table 3). 
 
Discussion 
The present study showed that SUA level was a possible surrogate marker of having 
vulnerable plaque in non-culprit lesions of ACS patients. To the best of our knowledge, this is the 
first report describing association between SUA level and coronary plaque characteristics by 
intravascular imaging in ACS patients. Although SUA has antioxidant capacities,
17
 significant 
correlations have been paradoxically reported between SUA level and surrogate markers of 
atherosclerosis such as inflammation or endothelial dysfunction.
18-20
 Uric acid may induce 
positive remodeling as process of coronary atherosclerosis via these underlying pathophysiologic 
mechanisms.
21
 Oxygen free radical is generated during purine metabolism by activity of xanthine 
oxidase.
22
 It causes endothelial dysfunction and impaired regulation of vascular tone.
23
 Recently 
it has also been shown that xanthine oxidase plays an important role in the transformation of 
macrophages into foam cells and the development of atherosclerotic plaque.
24
 
Previous studies have shown that elevated SUA level is associated with cardiovascular 
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events. In a series of 1,124 patients with acute MI, Kojima et al demonstrated higher 30-day 
major adverse cardiac events and long-term mortality in patients with higher SUA level compared 
to those with lower SUA level.
5
 Kaya et al showed higher rates of in-hospital and long-term 
major adverse cardiovascular events in STEMI patients with high SUA level than in those with 
low SUA level.
3
 Cardiovascular mortality, reinfarction, target vessel revascularization, and severe 
heart failure were observed more frequently in the high SUA group. 
There is little information about relation between SUA level and coronary plaque 
characteristics.
25, 26
 Elevated SUA level has been reported as a predictor of poor coronary blood 
flow following primary PCI.
27,28
 No-reflow or slow flow phenomenon occurs in patients with 
greater lipid content of coronary plaque.
10, 11
 The present study showed greater lipid and less 
fibrous components in the high tertile group than in the low and intermediate tertile groups. 
Utilizing IB-IVUS, Sano et al reported higher % lipid area and lower % fibrous area in plaque of 
patients with than without cardiovascular events during follow-up.
29 
There are some limitations in the present study. First, the number of patients was 
relatively small. Second, clinical information of long-term outcomes was not available, although 
elevated SUA level was suggested as an indicator of greater lipid content of coronary plaque. 
Third, we analyzed plaque which was only proximal to the culprit lesion. It made the studied 
segment shorter but the vessel size relatively uniform. The vessel size correlated with lipid 
content of coronary plaque.
30 
This is why we evaluated non-culprit plaque at the segment 
proximal to the culprit lesion. 
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Table 1. Baseline characteristics 
Variable Tertile 
p Value Low 
(n = 27) 
Intermediate 
(n = 27) 
High 
(n = 27) 
Men 17 (63%) 24 (89%) 25 (93%) 0.01 
Age (years) 65.5 ± 9.2 66.0 ± 14.3 63.8 ± 12.7 0.79 
Body mass index (kg/m
2
)
 
23.3 ± 3.5 23.5 ± 3.2 25.2 ± 3.2 0.08 
Hypertension 20 (74%) 16 (59%) 19 (70%) 0.49 
Diabetes mellitus 11 (41%) 7 (26%) 9 (33%) 0.59 
Dyslipidemia 17 (63%) 19 (70%) 20 (70%) 0.68 
Current smoker 10 (37%) 11 (41%) 11 (41%) 0.95 
Prior myocardial infarction 2 (7%) 2 (7%) 3 (11%) 0.86 
eGFR (ml/min/1.73m
2
)
 
85.1 ± 20.9 72.0 ± 17.6 60.3 ± 18.5 <0.001 
Serum uric acid (mg/dl) 4.0 ± 1.0 5.5 ± 0.4 7.6 ± 1.1 <0.001 
Culprit coronary artery     
Right 7 (26%) 7 (26%) 10 (37%)  
Left anterior descending 10 (37%) 12 (44%) 13 (48%)  
Left circumflex 10 (37%) 8 (30%) 4 (15%) 0.45 
Clinical presentation     
Unstable angina pectoris 3 (11%) 5 (19%) 4 (15%)  
NSTEMI 8 (30%) 9 (33%) 14 (52%)  
STEMI 16 (59%) 13 (48%) 9 (33%) 0.35 
Medication on admission    
Statin 8 (30%) 9 (33%) 9 (33%) 0.95 
ACE-I or ARB 7 (26%) 13 (48%) 11 (41%) 0.24 
Calcium channel blocker 8 (30%) 7 (26%) 7 (26%) 0.94 
Diuretic 1 (4%) 1 (4%) 5 (19%) 0.08 
Hypertension was defined by systolic blood pressure ≥140 mm Hg, diastolic blood 
pressure ≥90 mm Hg, or taking antihypertensive medications. Diabetes mellitus was defined by 
glycated hemoglobin ≥6.5%, or taking diabetic medications. Dyslipidemia was defined by 
high-density lipoprotein <40 mg/dl, low-density lipoprotein >140 mg/dl, fasting triglyceride 
>150 mg/dl, or taking lipid-lowering medications. eGFR = estimated glomerular filtration rate; 
NSTEMI = non–ST-segment elevation myocardial infarction; STEMI = ST-segment elevation 
myocardial infarction; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin 
receptor blocker. 
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Table 2. Intravascular Ultrasound Analysis 
Variable Tertile 
p Value Low 
(n = 27) 
Intermediate 
(n = 27) 
High 
(n = 27) 
Lesion length (mm) 15.6 ± 10.1 20.0 ± 12.6 14.2 ± 10.1 0.14 
Minimum lumen area (mm
2
) 8.2 ± 2.9 6.1 ± 2.6 7.6 ± 3.8 0.05 
Vessel area (mm
2
) 16.4 ± 4.3 14.4 ± 5.0 17.5 ± 4.8 0.06 
Plaque area (mm
2
) 8.3 ± 3.6 8.3 ± 3.9 9.8 ± 3.4 0.22 
Lumen volume (mm
3
/mm) 10.7 ± 3.2 9.9 ± 3.1 10.6 ± 3.2 0.60 
Vessel volume (mm
3
/mm) 17.4 ± 4.4 16.7 ± 4.1 19.4 ± 3.7 0.05 
Plaque volume (mm
3
/mm) 6.7 ± 2.2 7.4 ± 2.7 8.6 ± 2.4 0.01 
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Table 3. Predictors of % Lipid Plaque Volume 
Variable 
 
Univariate Multivariate 
r p Value  p Value 
Dyslipidemia 0.15 0.19 0.12 0.25 
Current smoker 0.15 0.18 0.15 0.16 
eGFR (ml/min/1.73m
2
)
 
-0.17 0.14 -0.02 0.88 
Serum uric acid (mg/dl) 0.35 0.001 0.34 0.007 
eGFR: estimated glomerular filtration rate. 
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Figure 1. Study flow chart. ACS = acute coronary syndrome; CPA = cardiopulmonary arrest; 
IVUS = intravascular ultrasound; PCI = percutaneous coronary intervention; SUA = serum uric 
acid. 
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Figure 2. Integrated backscatter intravascular ultrasound analysis. 
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Figure 3. Representative images of grayscale and integrated backscatter intravascular ultrasound 
of non-culprit coronary plaques in patients with low (A) and high (B) serum uric acid (SUA) 
levels. The percentage of lipid area and fibrosis area are 36.9% and 57.3% in the patient with a 
low SUA level and 69.6% and 29.6% in the patient with a high SUA level, respectively. Blue = 
lipid area, green = fibrosis area, yellow = dense fibrosis area, red = calcium deposit area. 
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